Last updated: February 20, 2026
What is ONSURA and what is its market positioning?
ONSURA (ubrogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed by AbbVie. It targets acute treatment of migraine in adult patients, specifically designed for rapid relief. Approved by the FDA in December 2019, ONSURA functions as a non-opioid, non-vasoconstrictive alternative for migraine attacks, competing directly with agents like ergotamines and triptans.
What are the market fundamentals?
Market size and growth
The global migraine drugs market was valued at approximately USD 4.9 billion in 2022. Compound Annual Growth Rate (CAGR) projections forecast 5-7% growth through 2030, driven by increased prevalence, improved diagnosis, and rising awareness.
Prevalence and target population
- Approximately 1 billion people worldwide suffer from migraine.
- In the U.S., 39 million adults have migraine, representing about 12% of the adult population.
- Estimated that 42% seek medical treatment, with about 50% receiving prescription drugs.
Competitive landscape
ONSURA faces competition from:
- Erenumab (Aimovig): CGRP monoclonal antibody, approved 2018, used for prevention.
- Rimegepant (Nurtec ODT): Oral CGRP receptor antagonist for acute and preventive treatment, approved 2020.
- Ubrogepant (Abby’s NEURO): Launched in 2019, sales records are emerging.
Sales figures for existing drugs provide context:
| Drug |
Year of FDA Approval |
Indication |
2022 U.S. Sales (USD millions) |
| Erenumab |
2018 |
Prevention |
861 |
| Rimegepant |
2020 |
Acute & Prevention |
350 (est.) |
| ONSURA (ubrogepant) |
2019 |
Acute |
150 (est.) |
Pricing and reimbursement
Prescription cost per treatment:
- ONSURA: Approx. USD 8,000-$9,500 annually, based on wholesale acquisition cost.
- Insurance coverage varies; CMS reimbursement policies enacted since 2020 favor novel therapeutics with demonstrated benefits over older agents.
Clinical efficacy
ONSURA demonstrated:
- Pain freedom at 2 hours in 20-22% of patients versus 15% with placebo.
- Pain relief at 2 hours in 58-60% versus 45% with placebo.
- Rapid onset with low incidence of adverse events (~4%).
Comparison with rimegepant shows comparable efficacy with a slightly better tolerability profile.
What are the key investment drivers?
Market penetration and patient adoption
- Early adoption in neurology clinics.
- Expansion into primary care settings.
- Prescription growth driven by formulary inclusion and physician education.
Pricing strategy and reimbursement
- Premium pricing offsets limited initial market share.
- Strategic partnerships with payers to improve reimbursement.
Regulatory environment
- Preference for oral agents accelerates adoption.
- Pending approval of extended indications (e.g., chronic migraine).
Pipeline and lifecycle management
- Abbott/Takeda’s ubrogepant pipeline for prevention.
- Development of combination therapies.
What are the risks and challenges?
Competition risk
- Established market presence of monoclonal antibodies for prevention.
- Fast-growing oral CGRP antagonists (e.g., Nurtec ODT).
Patent exclusivity and biosimilar threat
- Patent expiration timelines are uncertain but likely beyond 2025.
- Biosimilars not applicable due to oral chemistry, but generics may enter after patent expiry.
Market access and reimbursement hurdles
- Variability across Medicaid, Medicare, and private insurers.
- Potential formulary exclusions affecting sales.
Clinical and safety considerations
- Long-term safety data limited; ongoing surveillance required.
- Side effects such as liver enzyme elevation observed in some trials.
Investment outlook
Given the expanding migraine market, increasing penetration of oral CGRP antagonists, and ONSURA’s clinical profile, the drug holds growth potential. However, competition from established biologics and rapid adoption of existing oral agents may temper short-term sales growth.
AbbVie’s strategic focus on expanding indications and pipeline development supports a positive long-term outlook. Near-term, sales may be constrained by market access hurdles and competitive pressure.
Key takeaways
- ONSURA addresses a significant unmet need for acute migraine treatment with favorable efficacy and safety.
- It operates in a growing market with multiple competitors, notably Nurtec ODT and Aimovig.
- Reimbursement policies and formulary placement will influence sales.
- Long-term growth depends on prescription adoption, pipeline development, and market dynamics.
- Investors should monitor clinical trial progress, regulatory changes, and competitive developments.
FAQs
-
How does ONSURA compare clinically to other migraine treatments?
ONSURA demonstrates comparable efficacy to rimegepant with a favorable safety profile, especially in rapid relief of acute migraine.
-
What is the current market penetration of ONSURA?
Sales are modest compared to competitors, with estimated 2022 U.S. sales at around USD 150 million, reflecting early-stage adoption.
-
What regulatory approvals are pending for ONSURA?
The drug is FDA approved; future approvals may include expanded indications for chronic migraine.
-
What are the main barriers to growth for ONSURA?
Competition from established therapies, reimbursement challenges, and market penetration hurdles.
-
Is patent protection sufficient for ONSURA's market exclusivity?
Patent life extends beyond 2025, but biosimilar threats are unlikely due to the drug’s oral small molecule chemistry.
References
[1] MarketWatch. (2023). Migraine drugs market analysis.
[2] FDA. (2019). ONSURA (ubrogepant) approval announcement.
[3] IQVIA. (2022). US migraine market sales data.
[4] U.S. Census Bureau. (2022). Migraine prevalence statistics.
[5] CDC. (2021). Migraine and headache statistics.
